- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.06. | Express Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies | ||
| 16.06. | FDA staff scrutinizes evidence supporting Moderna's flu vaccine | ||
| 16.06. | Edgewise heart drug passes key trial test | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | ||
| 16.06. | [Podcast] (Season 2) The Progress Profile: Alzheimer's Research in Focus | ||
| 15.06. | Medicare drug price rule may target under-the-skin Keytruda and Opdivo | ||
| 15.06. | Lilly scores early positive data for new JAK drug | ||
| 15.06. | J&J multiple myeloma drug gains edge in earlier stage disease | ||
| 15.06. | Planning a successful pivot from lab to clinic | ||
| 15.06. | Celiac disease is entering a new era of therapeutic innovation | ||
| 12.06. | Rapport 'fully prepared' to launch seizure drug solo, CEO says | ||
| 11.06. | Summit pulls $500M share sale a day after announcing it | ||
| 11.06. | Novartis RNA drug acquired in $12B Avidity deal notches a trial win | ||
| 11.06. | Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy | ||
| 11.06. | Takeda's $4B TYK2 drug tops Bristol Myers' Sotyktu in head-to-head test | ||
| 10.06. | Ethyreal starts up with $101M and takes aim at a pair of immune diseases | ||
| 10.06. | Sanofi stops immune drug trial in latest research setback | ||
| 10.06. | Parabilis sets a record with a $670M biotech IPO | ||
| 10.06. | AstraZeneca's 'extensive' obesity drug push; $125M for ultrasound-aided genetic medicine | ||
| 09.06. | Merck, Gilead report mixed outcomes in key lung cancer, HIV studies | ||
| 09.06. | Stealthy startup Treeline plans a reverse merger | ||
| 09.06. | GSK boosts cancer pipeline with $11B Nuvalent buyout | ||
| 08.06. | City banks nearly $100M for next-gen RNAi drugs | ||
| 08.06. | Roche stakes $700M on Nurix's protein-degrading drug | ||
| 08.06. | Tango data add to growing momentum for pancreatic cancer drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.